The subcutaneously administered trastuzumab contains the same monoclonal antibody as the intravenous formulation at a dose of 600 mg per 5-mL vial, plus a recombinant human hyaluronidase, to be used every 3 weeks. The hyaluronidase is used to increase the permeability of the extracellular matrix, allowing for administration of higher volumes and enhanced absorption of the drug.
In March of this year, the FDA approved a subcutaneously administered version of brand-name trastuzumab, Herceptin. The product, trastuzumab and hyaluronidase-oysk, was approved under the brand name Herceptin Hylecta.
The subcutaneously administered trastuzumab contains the same monoclonal antibody as the intravenous formulation at a dose of 600 mg per 5-mL vial, plus a recombinant human hyaluronidase, to be used every 3 weeks. The hyaluronidase is used to increase the permeability of the extracellular matrix, allowing for administration of higher volumes and enhanced absorption of the drug.
On the heels of the approval, researchers have now reported a final analysis of the HannaH trial, a phase 3 study that helped secure the FDA’s approval. In the trial 294 patients with ERBB2—positive early breast cancer were treated with 8 cycles of chemotherapy and subcutaneous trastuzumab, and 297 patients were treated with chemotherapy plus the intravenous trastuzumab. Patients then received another 10 cycles of their assigned trastuzumab in the adjuvant setting for 1 year.
Six-year event-free survival rates were 65% in both arms (hazard ratio [HR], 0.98; 95% CI, 0.74-1.29) and overall survival rates were 84% in both arms (HR, 0.94; 95% CI, 0.61-1.45).
The incidence of adverse events (AEs) was comparable between arms, with 97.6% and 94.6% of patients reporting AEs in the subcutaneous and intravenous groups, respectively. Serious AEs were reported in 21.9% and 15.1% of patients, respectively, and the incidence of cardiac AEs was also similar, at 14.8% and 14.1%, respectively, even for patients in the lowest body-weight quartile.
These data, which support the long-term comparability in terms of efficacy and safety of the subcutaneous trastuzumab versus the intravenous option, will be welcome reassurance for patients and providers who seek to reduce the burden of chair time for lengthy infusions with trastuzumab. The newly approved subcutaneous formulation has also been shown to save on costs in other regulatory territories where the drug is already widely in use.
For developers of intravenously administered biosimilar products, however, these results may be cause for business-related concern; in the United States, 5 biosimilars of trastuzumab have been approved (Ontruzant, Herzuma, Kanjinti, Ogivri, and Trazimera), and the first of these agents are expected to launch as early as this year. However, all of these biosimilars are in intravenous formulations, with no biosimilar subcutaneous options. It remains to be seen how deeply discounted these biosimilars will be, and whether those cost savings will be able to outweigh the benefits of a subcutaneous administration option.
Reference
Jackisch C, Stroyakovskiy D, Pivot X, et al. Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH phase 3 randomized clinical trial. JAMA Oncol. 2019;5(5):e190339. doi: 10.1001/jamaoncol.2019.0339.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in New Zealand in 2022.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.